A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT ID: NCT01935518

Last Updated: 2013-09-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-09-30
• Study Completion Date: 2015-05-31

Brief Summary

This study will examine whether fasudil is effective and safe in treating patients with amyotrophic lateral sclerosis (ALS).

Detailed Description

This is an open labeled, single center clinical study with placebo of historical researches as control. 10 patients will be enrolled in the study. The basic treatment is riluzole, 50mg twice a day. For the procedure, patients will take fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later, patients will repeat the fasudil treatment. All the patients will be followed up for 6 months. The primary outcome was the decline rate of ALSFRS-R. The secondary outcomes are the survival time, endpoint time(death, tracheotomy and continuous ventilator-dependent), forced vital capacity (FVC), the short form health survey (SF-36), evaluation of cognitive function (verbal fluency and Frontal Behavioral Inventory Scale) and safety.

Conditions

Amyotrophic Lateral Sclerosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Fasudil

All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.

Group Type: EXPERIMENTAL

Fasudil

Intervention Type: DRUG

All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.

Interventions

Fasudil

All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Clinical diagnosis of laboratory-supported probable, probable, or definite ALS
• Age: 18-70 years
• Disease duration: 3-36 months
• Forced vital capacity: at least 60% of predicted
• ALSFRS-R: at least 30, respiratory items: at least 10
• Decline of ALSFRS-R in the last 3 months before enrollment: 1-8
• Must take riluzole, on a stable dose for at least 30 days prior to baseline visit with no serious side effects. They must continue the riluzole treatment for at least 6 months after enrollment.
• Patients of childbearing potential must be using an effective method of birth control
• Willing and able to give informed consent

Exclusion Criteria

• Familial ALS
• Pregnant or nursing women
• Patients after tracheotomy or continuous ventilator-dependent (time with non-invasive ventilator more than 22 hours per day for 7 consecutive days.)
• After percutaneous endoscopic gastrostomy
• Alanine Transaminase (ALT) or Aspartate Transaminase (AST): at least 3 times the upper limit of normal
• Abnormal creatinine or urea nitrogen
• Severe cardiac disease, pulmonary disease, hematic disease, autoimmune disease, mental disease, dementia and substance abuse
• History of malignancy
• History of intracranial hemorrhage
• History of severe bleeding of digestive tract, lungs, nose and skin
• Allergic to fasudil
• Participating in other clinical studies or using other investigational drugs at present

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking University Third Hospital

OTHER

Sponsor Role: lead

Responsible Party

Fan Dongsheng

Chairman of the department of neurology of Peking University Third Hospital

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Dongsheng Fan, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Peking University Third Hospital

Locations

Peking University Third Hospital

Beijing, , China

Site Status: RECRUITING

Countries

China

Central Contacts

Dongsheng Fan, MD, PhD

Role: CONTACT

Phone: 0086-15611908107

Email: dsfan@sina.com

Facility Contacts

Xiaolu Liu, MD

Role: primary

Other Identifiers

PUTH-2013121

Identifier Type: -

Identifier Source: org_study_id